Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc > TIME TO ROLL

<< Previous

Bullboard Posts

Next >>

Post by angeloeton Apr 14, 2022 9:53am

203 Views

Post# 34603429

TIME TO ROLL

With Echelon finally out of the way, looks like we're about to fly. Time to ride this. 1.2 billion in revenue alone from ACP, and that doesn't even include the Shapiro deal, 430 million patients at 20,000$s per treatment, even if they have just a 10% share of that market -43bil$s in revenue-. We're about to make paper son, loooooool !!

<< Previous

Bullboard Posts

Next >>

This battery metals stock is on a path to the global stage